Ensysce Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated August 9, 2022, reports on events occurring on August 8, 2022. Ensysce Biosciences, Inc. (Ensysce), a Delaware corporation, completed the second closing of a previously announced $8.0 million financing arrangement with institutional investors.
Key Financial Metrics and Transaction Details
The filing details the issuance of debt and equity instruments at the second closing:
- Debt Issuance: Senior secured convertible promissory notes with an aggregate principal amount of $4.24 million for a purchase price of $4.0 million.
- Equity Issuance: Warrants to purchase 4,667,890 shares of common stock.
- Note Terms: 18-month term, 6.0% annual interest rate, and a 6% original issue discount.
- Conversion Price: $0.5450 per share (10% premium to the average stock price prior to the first closing).
- Warrant Terms: Exercise price of $0.7085 (30% premium to conversion price), exercisable for five years.
- Security: Obligations are secured by all assets of the Company and its subsidiaries and guaranteed jointly and severally by subsidiaries.
Material Changes and Modifications
Concurrent with the second closing, the Company entered into a Letter Agreement modifying prior terms regarding outstanding 2021 Senior Secured Convertible Notes:
- Conversion Price Reduction: The conversion price for the remaining balance of the 2021 Notes was reduced from $0.78 to $0.35 for the period from August 8, 2022, until October 1, 2022.
- Maturity Extension: The 2021 Notes were extended to be due and payable on October 10, 2022, requiring satisfaction in cash.
- Registration Rights: The Company agreed to register additional shares of common stock required upon conversion of the Senior Secured Convertible Notes.
Outlook, Risks, and Redemption Obligations
The Company faces specific redemption obligations under the new notes:
- Monthly Redemptions: Commencing November 1, 2022, the Company must redeem 1/15th of the original principal amount monthly, plus accrued interest and other amounts.
- Payment Options: The Company may pay redemptions in cash (with an 8% premium) or in conversion shares, subject to specific price floors ($0.1003) and equity conditions.
- Risks: The filing includes standard forward-looking statement disclaimers. Actual results may vary due to risks discussed in periodic SEC filings, including the Company's ability to meet redemption obligations and the impact of dilution from warrant exercises and note conversions.
Investor Verification Checklist
- Verify the Company's current cash position and liquidity to meet the mandatory monthly redemption schedule starting November 1, 2022.
- Confirm the total outstanding principal of the 2021 Senior Secured Convertible Notes and the impact of the reduced conversion price ($0.35) on potential dilution.
- Review the Security Agreement and Patent Security Agreement to understand the extent of assets pledged as collateral.
- Monitor the stock price relative to the $0.1003 floor required to pay redemptions in shares rather than cash.
- Check for any subsequent filings regarding the October 10, 2022, cash repayment deadline for the 2021 Notes.